lurbinectedin news

All news on lurbinectedin (also known as PM01183 and Zepzelca): plants, production capacities, investments and involved companies.

10 June 2026

Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer

FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.

Who will be producing lurbinectedin in the future?

Find out with chemXplore Alpha

Learn more